Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

Three-Color SUV<sub>LV</sub>-Normalized SPECT/CT to Visualize Dynamic Pulmonary Perfusion in Chronic Thromboembolic Pulmonary Hypertension.

Circulation reports·2026
Same author

Long-term outcomes of stent-based pulmonary angioplasty for isolated peripheral pulmonary artery stenosis.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Phase 3, Open-Label Multicenter Study of Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension.

JACC. Asia·2026
Same author

Real-world treatment practices of selexipag and parenteral prostacyclin (PGI<sub>2</sub>) analogs for pulmonary arterial hypertension in Japan: Retrospective study of the Japan PH Registry.

Journal of cardiology·2026
Same author

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment.

EBioMedicine·2025

Related Experiment Video

Updated: Jun 27, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

[Continuous intravenous prostacyclin therapy].

Katsumasa Miyaji1, Hiromi Matsubara

  • 1National Hospital Organization Okayama Medical Center.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 5, 2008
PubMed
Summary

Continuous intravenous prostacyclin therapy is the recommended treatment for severe pulmonary arterial hypertension. Despite potential complications, its effectiveness makes it essential for critically ill patients.

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Context:

  • Pulmonary arterial hypertension (PAH) requires effective treatment strategies.
  • Intravenous prostacyclin therapy is a guideline-recommended standard for severe PAH.
  • Controlled trials support its use in the United States, Europe, and Japan.

Purpose:

  • To review the established role and administration complexities of intravenous prostacyclin therapy in severe pulmonary arterial hypertension.
  • To emphasize the critical importance of this treatment despite potential adverse events.

Summary:

  • Intravenous prostacyclin therapy, including epoprostenol, is the standard treatment for severe pulmonary arterial hypertension (PAH).
  • Guidelines in the US, Europe, and Japan recommend it for critically ill PAH patients based on controlled trials.

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Experiment Videos

Last Updated: Jun 27, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

  • Epoprostenol's short half-life necessitates continuous infusion via a central venous catheter and pump, posing risks like infection and device malfunction.

    • Impact:

    • Highlights the critical need for continuous intravenous prostacyclin therapy in severe PAH.
    • Underscores that the benefits of this effective treatment outweigh the risks associated with its administration complexities.
    • Reinforces the importance of adhering to established treatment protocols for managing severe pulmonary arterial hypertension.